5:14 PM
 | 
Feb 07, 2014
 |  BC Extra  |  Clinical News

ADX71149 misses in Phase IIa for anxious depression

Addex Therapeutics Ltd. (SIX:ADXN) said top-line data from a Phase IIa trial evaluating ADX71149 to treat major depressive disorder (MDD) with anxiety symptoms do not support further development of the compound for anxious depression. In the...

Read the full 168 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >